Cypherpunk Technologies reported a $37.8 million loss in the first half of 2026 despite holding 323,394 ZEC valued at about $157 million, more than double its $74 million market cap. The company is pivoting to fund Phase 3 trials for its cancer drug Sirexatamab, which failed to show benefits in Phase 2 but received FDA fast track status. With only $7.6 million in cash and ongoing losses, Cypherpunk faces a tough financial path, balancing its crypto asset accumulation goal with costly drug development. The company is seeking external funding options but has not secured any partnerships yet, raising investor concerns about its future.
Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a ...
Signet Jewelers reported Q2 fiscal 2027 earnings of $2.19 per share, surpassing analyst estimates of $1.69 by nearly 30%, marking its sixth consecutive quarter of earnings beats. Although revenue slightly missed expectations at $1.528 billion versus ...
UBS increased its price target for ABM Industries to $51.50 following the company's strong quarterly earnings and revenue growth. ABM reported a 4.2% revenue increase to $2.32 billion and a 19% rise in net income to $49.7 million, alongside strong ca...
Chewy reported quarterly earnings of $0.36 per share, doubling analyst estimates of $0.18, with net income rising to $80.5 million from $62 million a year ago. Quarterly revenue reached $3.33 billion, slightly above expectations, marking a 7.3% incre...
AeroVironment, a leading drone maker, is set to report its Q3 earnings on September 9, 2026, with analysts expecting EPS between $0.22 and $0.25 and revenue near $452-$456 million. The company recently secured major contracts worth over $865 million ...
